ATE247949T1 - Arzneistoffverabreichungssystem mit zweistufigem targeting - Google Patents

Arzneistoffverabreichungssystem mit zweistufigem targeting

Info

Publication number
ATE247949T1
ATE247949T1 AT98962780T AT98962780T ATE247949T1 AT E247949 T1 ATE247949 T1 AT E247949T1 AT 98962780 T AT98962780 T AT 98962780T AT 98962780 T AT98962780 T AT 98962780T AT E247949 T1 ATE247949 T1 AT E247949T1
Authority
AT
Austria
Prior art keywords
drug
delivery system
drug delivery
target
cells
Prior art date
Application number
AT98962780T
Other languages
English (en)
Inventor
Katarina Edwards
Joergen Carlsson
Stefan Sjoeberg
Original Assignee
Katarina Edwards
Joergen Carlsson
Stefan Sjoeberg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Katarina Edwards, Joergen Carlsson, Stefan Sjoeberg filed Critical Katarina Edwards
Application granted granted Critical
Publication of ATE247949T1 publication Critical patent/ATE247949T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
    • A61K41/0095—Boron neutron capture therapy, i.e. BNCT, e.g. using boronated porphyrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT98962780T 1997-12-05 1998-12-04 Arzneistoffverabreichungssystem mit zweistufigem targeting ATE247949T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704549A SE513149C2 (sv) 1997-12-05 1997-12-05 Läkemedelsdistributionssystem med tvåstegsmålsökning, till specifika celler eller vävnad och till dess cellkärna
PCT/SE1998/002231 WO1999029302A1 (en) 1997-12-05 1998-12-04 Drug delivery system with two-step targeting

Publications (1)

Publication Number Publication Date
ATE247949T1 true ATE247949T1 (de) 2003-09-15

Family

ID=20409286

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98962780T ATE247949T1 (de) 1997-12-05 1998-12-04 Arzneistoffverabreichungssystem mit zweistufigem targeting

Country Status (10)

Country Link
US (1) US6562316B1 (de)
EP (1) EP1033972B1 (de)
JP (1) JP2001525356A (de)
AT (1) ATE247949T1 (de)
AU (1) AU745059B2 (de)
CA (1) CA2312767C (de)
DE (1) DE69817602T2 (de)
DK (1) DK1033972T3 (de)
SE (1) SE513149C2 (de)
WO (1) WO1999029302A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0963758A3 (de) * 1998-05-07 2000-03-22 Universiteit Gent Synthetische polyamiosaure Komplexen zur Verabreichung von Nukleinsäuren zur Zielzellen
DE19905094C1 (de) * 1999-02-01 2000-10-12 Schering Ag Gadolinium (III)-Komplexe sowie ihre Verwendung für Zweischritt Strahlentherapieformen und diese enthaltende pharmazeutische Mittel
US7238368B2 (en) 1999-04-23 2007-07-03 Alza Corporation Releasable linkage and compositions containing same
US7303760B2 (en) 1999-04-23 2007-12-04 Alza Corporation Method for treating multi-drug resistant tumors
ATE340592T1 (de) * 1999-04-23 2006-10-15 Alza Corp Konjugate enthaltend eine spaltbare bindung zur anwendung in einem liposom
US7591995B2 (en) 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
US20060177416A1 (en) 2003-10-14 2006-08-10 Medivas, Llc Polymer particle delivery compositions and methods of use
EP1877099B1 (de) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutische konjugate beinhaltend ein lysosomales enzym, polysialinsäure und eine zielkomponente
EP1926780B1 (de) 2005-09-22 2013-08-14 Medivas, LLC Bis-( -amino)-diol-diester-haltige poly(esteramid) und poly(esterurethan)-zusammensetzungen und verwendungsverfahren
BR122020010601B8 (pt) 2008-12-16 2021-07-27 Genzyme Corp conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas
WO2010114901A1 (en) 2009-03-31 2010-10-07 The Board Of Trustees Of The University Of Arkansas Method of controlled drug release from a liposome carrier
US10702614B2 (en) * 2011-02-15 2020-07-07 Albert Einstein College Of Medicine Radiobacteria for therapy of cancer
EP3159368A1 (de) 2011-06-23 2017-04-26 DSM IP Assets B.V. Neue biologisch abbaubare polyesteramid-copolymere zur arzneimittelabgabe
US9873765B2 (en) 2011-06-23 2018-01-23 Dsm Ip Assets, B.V. Biodegradable polyesteramide copolymers for drug delivery
US9849087B2 (en) 2011-11-08 2017-12-26 The Board Of Trustees Of The University Of Arkansas Methods and compositions for X-ray induced release from pH sensitive liposomes
CN107106509B (zh) 2014-12-18 2021-11-30 帝斯曼知识产权资产管理有限公司 用于递送酸敏感药物的药物递送系统
US11492670B2 (en) 2015-10-27 2022-11-08 The Broad Institute Inc. Compositions and methods for targeting cancer-specific sequence variations
US20220273382A1 (en) 2019-08-01 2022-09-01 Indian Institute Of Science A method for locomotion of a nanorobot and implementations thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2613937B1 (fr) * 1987-04-17 1989-07-21 Ire Celltarg Sa Ligands specifiques de recepteurs d'hormones steroides utiles pour la therapie ciblee ou l'imagerie medicale notamment du cancer
US5328678A (en) * 1987-11-04 1994-07-12 Vestar, Inc. Composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy
US5620689A (en) * 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
IE914220A1 (en) * 1990-12-10 1992-06-17 Akzo Nv Labelled, modified oligonucleotides
JP3193379B2 (ja) * 1991-10-31 2001-07-30 アメリカ合衆国 化学療法剤としてのビストリアゼン類
US5750390A (en) * 1992-08-26 1998-05-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for treatment of diseases caused by expression of the bcl-2 gene
US5674977A (en) * 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US5648532A (en) * 1993-06-03 1997-07-15 The Regents Of The University Of California Compositions for boron neutron capture therapy and methods thereof
US5939277A (en) * 1993-10-15 1999-08-17 Rakowicz-Szulczynska; Eva M. Detection and treatment of breast and gynecological cancer
US6180766B1 (en) * 1993-12-02 2001-01-30 Raymond F. Schinazi Nucleosides and oligonucleotides containing boron clusters
US5599796A (en) * 1993-12-02 1997-02-04 Emory University Treatment of urogenital cancer with boron neutron capture therapy
JPH09510352A (ja) * 1994-03-15 1997-10-21 プリズム ファーマシューティカルズ，インコーポレイティド 遺伝子療法及び前部の眼疾患のためのヘパリン結合成長因子
US5630786A (en) * 1994-06-27 1997-05-20 Ionix Corporation Boron neutron capture enhancement of fast neutron therapy
US5756668A (en) * 1994-11-15 1998-05-26 The Johns Hopkins University School Of Medicine Hypermethylated in cancer polypeptide, HIC-1
US5643599A (en) * 1995-06-07 1997-07-01 President And Fellows Of Harvard College Intracellular delivery of macromolecules
HUP9901790A3 (en) * 1996-05-08 2010-11-29 Nika Health Products Ltd Cationic virosomes as transfer system for genetic material
WO1997045442A1 (en) * 1996-05-24 1997-12-04 Imperial College Of Science Technology And Medicine Polycationic sterol derivatives as transfection agents

Also Published As

Publication number Publication date
AU745059B2 (en) 2002-03-07
CA2312767C (en) 2009-04-07
SE9704549L (sv) 1999-06-06
CA2312767A1 (en) 1999-06-17
EP1033972A1 (de) 2000-09-13
JP2001525356A (ja) 2001-12-11
SE513149C2 (sv) 2000-07-17
AU1793899A (en) 1999-06-28
US6562316B1 (en) 2003-05-13
DE69817602T2 (de) 2004-06-24
DK1033972T3 (da) 2003-12-22
SE9704549D0 (sv) 1997-12-05
DE69817602D1 (de) 2003-10-02
EP1033972B1 (de) 2003-08-27
WO1999029302A1 (en) 1999-06-17

Similar Documents

Publication Publication Date Title
ATE247949T1 (de) Arzneistoffverabreichungssystem mit zweistufigem targeting
NZ336511A (en) Treating prostatic diseases using delayed and/or sustained release formulations of activated vitamin D
EA200000087A1 (ru) Повышение эффективности терапии гиперпролиферативных состояний с помощью антиоксиданта
EP1455840A4 (de) Behandlung von krebs bei menschen mit adenovirus-vektor tnf-alpha
Neuwelt et al. In vitro and animal studies of sodium thiosulfate as a potential chemoprotectant against carboplatin-induced ototoxicity
MY116474A (en) Potentiation of temozolomide in human tumour cells
AU3354500A (en) Dramatic simplification of a method to treat neoplastic disease by radiation
AU4338501A (en) Combination chemotherapy
AU2001236529A1 (en) Combination therapy for cancer
Dische Radiotherapy using the hypoxic cell sensitizer Ro 03-8799 in malignant melanoma
Looney et al. Solid tumor models for the assessment of different treatment modalities. XXII. The alternate utilization of radiotherapy and chemotherapy
WO2005013802A3 (en) Trefoil factor 3 (tff3) as a target for anti-cancer therapy
Hopkins et al. The effect of varying the time between irradiation and cyclophosphamide on growth response of hepatoma 3924A
AU6955396A (en) Combination therapy for advanced cancer comprising temozolomide and cisplatin
UA30257A (uk) Спосіб нормалізації тканинного обміну та відновлення морфофункціонального стану органів і тканин
ATE247468T1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
Nutting et al. Radiation Therapy and Soft Tissue Response
Meral et al. Role of vitamin E in decreasing the toxic effect of digoxin
Struwig Microcurrent therapy
RU94035764A (ru) Способ лечения онкологического заболевания
Stevenson et al. Beneficial liaisons: Radiobiology meets cellular and molecular biology
Wang Head and neck: Treatment of primary and relapsed nasopharyngeal carcinoma
Wittes Obstacles to Improved End-Results in Head and Neck Cancer
RU94021014A (ru) Способ лечения злокачественных опухолей методом фотодинамической терапии
RU2002106480A (ru) Способ лечения запущенных форм злокачественных опухолей

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties